Skip to main content
Premium Trial:

Request an Annual Quote

A New Option for Brain Cancer Patients

Premium

FDA approved a new device, Novocure's NovoTTF, that purports to treat brain tumors with "electrical energy fields," reports the Associated Press' Matthew Perrone. The device has been approved for patients with aggressive tumors that have come back after previous treatment with chemotherapy and other therapies. Novocure says the device uses electrical fields to disrupt cancer cell division with little effect on healthy cells, Perrone reports. Studies on the NovoTTF show that patients using it lived about as long as those taking chemotherapy — roughly six months — but with fewer side effects, he adds. One clinician tells Perrone that the device is a good second option for patients after primary treatment has failed, especially because it lacks the debilitating side effects that often accompany chemotherapy.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.